Global Point-of-Care Genetic Testing Market Size By Type (Type I, Type II), By Application (Diagnostic Labs, Bio-Pharmaceutical Industry), By Region, And Segment Forecasts, 2023 to 2032

The Global Point-of-Care Genetic Testing Market was valued at USD X billion in 2023 and is projected to reach USD Y billion by 2031, growing at a CAGR of Z% during the forecast period (2023-2031). The increasing demand for rapid and decentralized diagnostic solutions, advancements in genetic sequencing technologies, and growing applications in personalized medicine are driving market growth.

Point-of-care (POC) genetic testing enables quick and efficient genetic analysis at or near the patient site, eliminating the need for centralized laboratories. The expanding use of POC genetic tests in infectious disease detection, pharmacogenomics, cancer screening, and hereditary disease diagnostics is further fueling market demand.

Drivers

Rising Demand for Personalized Medicine

The increasing focus on precision medicine, which tailors treatments based on an individual's genetic profile, is boosting the adoption of point-of-care genetic testing. This is particularly significant in oncology and rare genetic disorders.

Advancements in Microfluidics & DNA Sequencing Technologies

Continuous technological advancements, including CRISPR-based diagnostics and lab-on-a-chip innovations, are improving test accuracy, speed, and affordability, making POC genetic testing more accessible.

Growing Prevalence of Infectious & Genetic Diseases

The rise in infectious diseases such as COVID-19, HIV, and tuberculosis, along with genetic disorders like cystic fibrosis and sickle cell anemia, is increasing the need for rapid, point-of-care genetic tests.

Restraints

High Cost of POC Genetic Testing Devices

Despite technological advancements, the high costs associated with point-of-care genetic testing devices and consumables remain a challenge, particularly in developing regions.

Regulatory & Ethical Concerns

The regulatory approval process for POC genetic tests is stringent, given the ethical concerns regarding genetic data privacy, potential misinterpretation of results, and patient anxiety.

Opportunities

Expansion in Emerging Markets

Countries in Asia-Pacific and Latin America are experiencing increasing healthcare investments and demand for decentralized diagnostics, creating lucrative opportunities for market players.

Integration of AI & Machine Learning in Genetic Testing

The application of AI-driven algorithms for genetic interpretation and decision-making in point-of-care settings is expected to enhance diagnostic accuracy and accelerate test processing times.

Development of Multiplexed POC Genetic Testing

Emerging multiplexed testing technologies allow simultaneous detection of multiple genetic markers, enhancing diagnostic efficiency and market adoption.

Market Insights

Market by System Type

PCR-based Point-of-Care Genetic Testing – Dominates the market due to its high sensitivity and specificity in genetic analysis.

Microarray-based POC Genetic Testing – Gaining traction in pharmacogenomics and hereditary disease detection.

Next-Generation Sequencing (NGS)-based POC Genetic Testing – Expected to witness the fastest growth due to its expanding applications in oncology and rare genetic disorders.

Market by End-Use

Hospitals & Clinics – The largest segment, as hospitals are integrating rapid genetic tests for bedside decision-making and emergency cases.

Diagnostic Laboratories – Growing adoption of decentralized genetic testing solutions for faster turnaround times.

Research Institutes & Academic Centers – Increasing focus on translational research and biomarker discovery.

Market by Regional Insights

North America – The largest market, driven by advanced healthcare infrastructure, high adoption of genetic testing, and strong government initiatives in precision medicine.

Europe – Significant growth, attributed to favorable regulatory policies and increasing funding for genomics research.

Asia-Pacific – The fastest-growing region, fueled by rising healthcare investments, expanding molecular diagnostics, and growing awareness of genetic diseases.

Competitive Scenario

Key players in the Global Point-of-Care Genetic Testing Market include:

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

Cepheid (Danaher Corporation)

QuantuMDx Group Ltd.

Lucira Health, Inc.

23andMe, Inc.

GenMark Diagnostics, Inc.

These companies are focusing on new product launches, strategic partnerships, and technological advancements to strengthen their market position.

Key Market Developments

2023: Thermo Fisher Scientific launched a new CRISPR-based point-of-care genetic test for rapid pathogen detection.

2024: Abbott expanded its POC genetic testing portfolio with a portable, AI-powered sequencing device for decentralized testing.

2025: Cepheid received FDA approval for its POC pharmacogenomics test to optimize personalized medicine treatments.

Scope of Work – Global Point-of-Care Genetic Testing Market

Report Metric Details

Market Size (2023) USD X billion

Projected Market Size (2031) USD Y billion

CAGR (2023-2031) Z%

Market Segments By System Type, End-Use, Region

Growth Drivers Demand for personalized medicine, advancements in genetic testing, rising prevalence of genetic diseases

Opportunities AI & machine learning integration, expansion in emerging markets, development of multiplexed genetic tests

FAQs

1) What is the current market size of the Global Point-of-Care Genetic Testing Market?

The market was valued at USD X billion in 2023 and is projected to grow significantly by 2031.

2) What is the major growth driver of the Global Point-of-Care Genetic Testing Market?

The rising demand for personalized medicine and advancements in genetic sequencing technologies are the key growth drivers.

3) Which is the largest region during the forecast period in the Global Point-of-Care Genetic Testing Market?

North America dominates the market, while Asia-Pacific is expected to witness the fastest growth.

4) Which segment accounted for the largest market share in the Global Point-of-Care Genetic Testing Market?

PCR-based point-of-care genetic testing holds the largest share, while NGS-based tests are expected to grow rapidly.

5) Who are the key market players in the Global Point-of-Care Genetic Testing Market?

Major players include Abbott Laboratories, Thermo Fisher Scientific, Cepheid, QuantuMDx, and 23andMe, Inc.